Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.samratpharmachem.com | |
Market Cap | 128.22 Cr. | |
Enterprise Value(EV) | 154.74 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 78.88 | Trailing Twelve Months Ending 2022-12 |
Price-Earning Ratio (PE) | 5.26 | Trailing Twelve Months Ending 2022-12 |
Industry PE | 31.70 | Trailing Twelve Months Ending 2022-12 |
Book Value / Share | 207.77 | Trailing Twelve Months Ending 2022-12 |
Price to Book Value | 2.00 | Calculated using Price: 415.00 |
Dividend Yield | 0.24 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.31 Cr. | 3,089,700 Shares |
FaceValue | 10 | |
Company Profile | ||
Samrat Pharmachem was incorporated on June 16, 1992, at Ankleshwar in Gujarat. It was promoted by Lalit Mehta & Rajesh Mehta. The company is currently manufacturing iodine salts & bromine salts. The finished products produced by the company are used in various industries like Pharmaceuticals, Chemicals, Food, Fertilizer, Salt, etc. The products of the company are well received in Indian & foreign markets. The company is a public limited company & its shares are listed & traded on the Bombay Stock Exchange & other bourses of India. The company is presently employing 30 people for its operations at Ankleshwar & Mumbai. |
1 Day |
|
+5.08% |
1 Week |
|
-7.02% |
1 Month |
|
-13.48% |
3 Month |
|
-43.39% |
6 Month |
|
-61.29% |
1 Year |
|
-11.57% |
2 Year |
|
+201.41% |
5 Year |
|
+220.67% |
10 Year |
|
+1650.61% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 1.86 | 2.38 | 2.21 | 12.07 | 19.01 | 7.96 | 19.10 | 19.77 | 44.95 | |
Return on Capital Employed (%) | 6.93 | 6.45 | 5.31 | 16.40 | 23.05 | 11.80 | 22.43 | 23.90 | 52.33 | |
Return on Assets (%) | 0.74 | 1.10 | 0.97 | 4.86 | 8.37 | 3.79 | 8.60 | 9.22 | 24.20 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 13 | 13 | 14 | 15 | 19 | 20 | 24 | 30 | 47 | 62 | |
Non Curr. Liab. | 1 | 1 | 2 | 2 | 1 | 1 | 0 | 0 | 0 | 7 | |
Curr. Liab. | 17 | 12 | 20 | 19 | 21 | 19 | 34 | 27 | 37 | 42 | |
Minority Int. | |||||||||||
Equity & Liab. | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 111 | |
Non Curr. Assets | 8 | 8 | 8 | 8 | 8 | 7 | 9 | 10 | 11 | 12 | |
Curr. Assets | 24 | 18 | 28 | 28 | 33 | 33 | 50 | 47 | 74 | 99 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 31 | 26 | 36 | 36 | 41 | 40 | 58 | 57 | 85 | 111 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-12 Rs. Cr. TTM |
Net Sales | 66 | 48 | 63 | 73 | 93 | 111 | 137 | 179 | 222 | 302 | |
Other Income | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | |
Total Income | 67 | 49 | 63 | 73 | 93 | 112 | 138 | 179 | 222 | 302 | |
Total Expenditure | -66 | -47 | -62 | -69 | -87 | -108 | -131 | -170 | -197 | -267 | |
PBIDT | 1 | 2 | 1 | 4 | 6 | 4 | 7 | 9 | 25 | 35 | |
Interest | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | |
Taxation | 0 | 0 | 0 | -1 | -2 | -1 | -2 | -2 | -6 | -9 | |
Exceptional Items | 0 | 0 | 0 | 0 | 0 | ||||||
PAT | 0 | 0 | 0 | 2 | 3 | 2 | 4 | 5 | 17 | 24 | |
Adjusted EPS | 1 | 1 | 1 | 6 | 10 | 5 | 14 | 17 | 56 | 79 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | -2 | 4 | -1 | 0 | -3 | 0 | 2 | -1 | 5 | 18 | |
Cash Fr. Inv. | -1 | 0 | 0 | -2 | 1 | -2 | 2 | -2 | -3 | -1 | |
Cash Fr. Finan. | 1 | -1 | 0 | 2 | 1 | 2 | -4 | 2 | -2 | -2 | |
Net Change | -2 | 2 | 0 | 0 | -1 | -1 | 1 | -1 | 0 | 14 | |
Cash & Cash Eqvt | 0 | 2 | 2 | 4 | 2 | 1 | 2 | 0 | 0 | 15 |
Fri, 17 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Please find enclosed the intimation letter dated March 16 2023 received from our Registrar and Share Transfer Agent Link Intime India Private Limited providing information regarding issue of duplicate share certificates to the shareholder(s) of the Company. The information is being submitted pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. |
Thu, 16 Mar 2023
Board Meeting Outcome for Outcome Of Board Meeting Held Today We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday March 16 2023 has appointed the following Directors on the recommendation of the Nomination and Remuneration Committee details of which are as under:1. Mr. Lalit Mehta (DIN: 00216681) re-appointed as the Chairman & Managing Director of the Company for a period of 3 years commencing from 1st April 20232. Mr. Rajesh Mehta (DIN: 00216731) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April 20233. Mr. Megh Mehta (DIN: 07287394) re-appointed as the Executive Director of the Company for a period of 3 years commencing from 1st April 2023The Board has adopted Succession Planning Policy under Regulation 17(4) of the Securities and Exchange Board of India (LODR) Regulations 2015 effective from 16th March 2023.The meeting of the Board of Directors of the Company commenced at 14:00 hrs and concluded at 15:30 hrs. |
Mon, 13 Mar 2023
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby furnish the details of loss of share certificates/ request for issue of duplicate share certificate received from our Registrar and Share Transfer Agent Link Intime India Private Limited on March 10 2023. |
Tue, 21 Mar 2023 |
|
|
|
|
|